The market has left medical device stocks in the dust, but heart monitor maker iRhythm Technologies is proving an exception.

Rhythm’s third quarter results were driven by strong commercial momentum across both core Zio Monitor and Zio AT products, ...

Rhythm (Nasdaq: IRTC) announced a major regulatory submission alongside third-quarter results that came in ahead of the ...

iRhythm Technologies IRTC recently announced initial research findings on the post-market, real-world performance of the Zio monitor, IRTC’s next-generation Zio long-term continuous monitoring (LTCM) ...

SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio ® long-term continuous ECG monitoring (LTCM) system, ...

iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...

Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups. Latest data showed ...

iRhythm Technologies, Inc. (IRTC) has officially launched its Zio monitor and long-term continuous (LTCM) ECG monitoring service in Austria, the Netherlands, Spain and Switzerland. With CE mark ...